Pepper Bio’s Post

📣 Synergizing Innovation: Uniting Biotech and Pharma for Advancing AI in Healthcare Join our panel of #BiotechLeaders as they discuss: ·  Collaborative models including joint ventures, licensing agreements, and research collaborations to pool resources, expertise, and data. ·  Optimizing AI applications in how partnerships between biotech and pharma entities can optimize AI applications by combining complementary strengths and accelerating the development of innovative AI-driven solutions ·  Opportunities and challenges to overcome barriers to maximize the potential of AI in advancing healthcare 🎙 Hear from: ·  Olivia Cavlan, Chief Corporate Development & Strategy Officer, Alchemab Therapeutics Ltd ·  Dr. D. Martin Alexander Gershon, MD, JD, MPH, Managing Partner & CIO, Endeavor Venture Fund & Venture Studio ·  Sergio Quezada, CSO, Achilles Therapeutics plc ·  Jon (Yu) Hu, CEO, Pepper Bio ·  Ping Yeh, CEO, Vocxi Health Find out more: https://lnkd.in/eNJghUgq #LSXWorld #Biotech #pharma

📣 Funding Biotech Innovation and Scaling Up Join our panel of #BiotechLeaders as they discuss: · How are companies using emerging technologies to give them an edge on innovation and accelerate pipelines? · As the dealmaking landscape shifts, how are companies coming up with new ways to prove value to investors who fund innovation? ·  What challenges do biotech CEOs face in negotiating partnerships? ·  How can companies scale up in order to deliver treatments to patients and returns to investors? 🎙 Hear from: ·  Ellen Donnelly, CEO, Abliva AB ·  Ann Belien, PhD, CEO & Founder, Rejuvenate Biomed ·  Matt Britz, CEO, AffyImmune Therapeutics ·  Daniel Passeri, CEO, Cue Biopharma ·  Rachel Ravens, CEO, 42Genetics Find out more: https://lnkd.in/eGgg9a2b #LSXWorld #Biotech 

As the biotech market recovers, it's not just trendy drug areas — like weight loss — attracting investor attention. Here's how one VC investor chooses which companies to back. Thanks Ayman AlAbdallah for the great conversations! #pharma #AI #biotech

At Jackson Hogg, we're proud to collaborate closely with AI-centric biotech firms globally. 💵 The AI health market is set to exceed $270 billion by 2030. Leading fundraisers include: 🌎 Relay Therapeutics (US) - $1,900M 🌏 XtalPi Inc. (China) - $780M 🌍 BenevolentAI (UK) - $294M 🖥 Over 250 companies are involved in AI and drug discovery, but it's a volatile space with few securing substantial funding or high valuations. 📉 Big pharma companies haven't made significant acquisitions in AI firms, possibly due to investors seeking tangible outcomes like marketable drugs over just technological innovation. 🤝 I believe M&As will be crucial going forward, with pharma companies likely to acquire AI platforms as they prove effective in drug discovery 🤔 Who will make the first move? #AIDrugDiscovery #AI #Biotech

Just as the Medici family were heralded as the Godfathers of the Renaissance for fostering an era of unparalleled cultural prosperity in Florence, today, Robert Nelsen and David Baker are laying the groundwork for a new age of health prosperity—the bio-renaissance. This is reminiscent of the Renaissance as multiple disciplines: AI x biology collide, enabled by big bets from financiers. Their latest venture, Xaira Therapeutics, has just launched with an unprecedented $1BN to revolutionize drug discovery through AI. May this be the day we look back as one that catalyzed the bio-renaissance. Here’s to hoping this initiative spawns drugs faster than ever before. The patients cannot wait. #BioRenaissance #Innovation #Healthcare #Biotechnology Vik Bajaj, Foresite Capital, Scott Gottlieb, New Enterprise Associates (NEA), Lux Capital, F-Prime Capital, Sequoia Capital, Lightspeed, Menlo Ventures, Two Sigma, SV Angel https://lnkd.in/gv5XXEsH

Argon AI (YC W24) is officially our second investment from the most recent Y Combinator batch and we couldn't be more excited! Argon AI is AI powered insights for pharma, biotech, and life sciences. "We help professionals get thorough answers to questions about clinical trials, existing treatments, healthcare landscape, and the competitive market in minutes rather than months." 🤯 Big shout out to co-founders Samy Danesh and Cyrus Jia. Thanks for bringing us along for your journey! #backedbySingularityCapital #pharma #biotech #lifesciences #venturecapital #venture #investment

You know what's a #Biotech 🧬 , right? Now, do you know what is a #TechBio 🤖 ? 🏢 TechBio is a rapidly growing subsector of the #LifeSciences industry that is transforming drug discovery and patient care. 💰 Investors are pouring significant capital into techbio, with a few select companies raising hundreds of millions of dollars. 🚀 The demand for new technologies in drug discovery is growing, and the overall trend is expected to continue. 🧠 Investors are looking for techbio companies with: 📌 A strong team with experience in both technology and biotech 📌 A clear business model that includes both partnering and developing their own assets 📌 A proven technology that can accelerate the drug development process and improve patient outcomes 🤝 Techbio companies face the challenge of: 📌 Finding the right business use cases for their technologies 📌 Differentiating themselves from other companies in the market 📌 Partnering with pharma and other industry players to de-risk and scale up their businesses 👉 Here's some advice for techbio companies from experts: 📌 Be wary of the hype and focus on the science 📌 Build a diverse team with experience in both technology and biotech 📌 Collaborate with pharma and other industry players 📌 Develop a clear business model that includes both partnering and developing your own assets 🚀 Techbio is a promising field with the potential to change how we do #drugdiscovery. With continued investment and innovation, techbio companies have the potential to make a significant impact on the healthcare industry. Claire Smith's article is here - https://lnkd.in/e6Z-C4mF #TechBio #LifeSciences #Innovation #DrugDiscovery #PatientCare #BIA

BioM Biotech Cluster Development GmbH’s highly anticipated event #BayOConnect - Forum for Biotech & LifeScience is coming up in Munich for the next two days! On July 2 the focus will be how to “Connect to Investment”, while on July 3, the spotlight will be on one of the biggest trends in Life Sciences exploring how to “Connect to AI”.   You won’t want to miss out on these program highlights featuring our clients:   “Risk and Reward - Comparative Strategies in Biotech Funding” June 2, 1:30 PM, with Olivier Litzka of Andera Partners   “Spotlight: Are we ready for AI?” June 3, 2:10 PM, with Dr. Friedrich von Bohlen of Molecular Health   Also, make sure to join the Pitch Session on June 2 at 2:30 PM, and connect with other like-minded, innovative start-ups such as AATec Medical and Mallia Therapeutics.   We can also recommend checking out the latest scientific posters during the breaks, including:    Secarna Pharmaceuticals: “Leading independent European antisense drug discovery & development company”  AATec Medical: “Novel Therapeutics for Globally Increasing Respiratory Diseases”   Schedule a meeting with our MC Services colleagues Eva Bauer, Dr. Cora Kaiser, Regina Lutz and Philipp Streng to find out more about how we support Life Science companies with expert Corporate Communications and Investor Relations insights: https://lnkd.in/d6ikVBPw   You can find the full agenda and the latest news from BayOConnect here: https://lnkd.in/dGMqmzYS #BayOConnect #LifeSciences #CorporateCommunications #InvestorRelations #MCServices #Networking #Biotech #Startup #Bayern #BioM 

What does Ochre Bio’s latest partnership illustrate about biotech’s business model evolution? Ochre Bio’s recent partnerships with GSK and Boehringer Ingelheim highlight a new era where biotech companies can generate revenue through data-driven collaborations, reducing reliance on dilutive equity funding and enabling a more independent growth path. Ochre Bio’s $37.5M partnership with GSK marks a shift in biotech business models, leveraging data and AI-driven platforms. These deals, focusing on data licenses and platform agreements, offer higher margins and lower risks than traditional asset-centered partnerships. More from Alex Brunicki, co-founder and partner at BACKED VC. Read the full article on EUVC insights. 🔽 https://buff.ly/3S7mWhV #biotech #businessmodel # #AI #equityfunding #EUVCinsights